Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

AGM Statement

18 May 2020 07:00

RNS Number : 1152N
Alliance Pharma PLC
18 May 2020
ย 

For immediate release

ย 

18 May 2020

ย 

ย 

ย 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

ย 

AGM Statement

ย 

Alliance Pharma plcย (AIM: APH), the international healthcare group, will hold its Annual General Meeting ("AGM") this morning. At the meeting, the Group's CEO, Peter Butterfield, will make the following statement:

ย 

"Firstly, on behalf of the Board, I would like to thank all the Alliance team around the world for their outstanding work in a period of extraordinary challenge as a result of the COVID-19 pandemic.

ย 

"As outlined in our preliminary results announcement last month, the majority of our employees have been working from home with minimal operational disruption to our business owing to our outsourced business model and robust IT systems. Our Shanghai office became fully operational again in early April and we look forward to fully re-opening our other offices around the world, in line with local government guidance.

ย 

"As expected, we have seen some impact on year to date revenues due to COVID-19, although we have been encouraged by the robustness of our product portfolio. We are now beginning to see a return in consumer confidence starting in China, a key market for Alliance, and we continue to anticipate that trading will be weighted to the second half of the year.

ย 

"Our supply chain remains robust and we have not experienced any significant supply disruption due to COVID-19. With a strong balance sheet and significant covenant headroom, the Board is confident that the Group is well placed to respond to increasing demand as local lockdown measures are eased.

ย 

"We look forward to providing an update on our first half trading performance and full year outlook in mid July 2020 in our scheduled half year trading update."

ย 

ย 

AGM 2020: Dial-in details for shareholders

Alliance's AGM is being held at 10am this morning. As detailed in the Notice of AGM, shareholders will not be able to attend the AGM in person, but shareholders are invited to follow the proceedings of the AGM remotely via the listen-only dial-in details given below.

UK Toll-free: 0800 3589473

PIN: 71891299#

UK Toll: 03333 000804

PIN: 71891299#

International dial-in numbers: https://events-ftp.arkadin.com/ev/docs/NE_W2_TF_Events_International_Access_List.pdf

PIN: 71891299#

For further information

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

ย 

Andrew Franklin, Chief Financial Officer

ย 

www.alliancepharma.co.uk

ย 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

ย 

ย 

ย 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

ย 

Corporate Broking: James Black

ย 

ย 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

ย 

Corporate Broking: Patrick Robb / Tejas Padalkar

ย 

ย 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or in-license the rights to more than 90 consumer healthcare and pharmaceutical products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

ย 

ย 

ย 

ย 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
ย 
END
ย 
ย 
AGMKKPBDABKDOPD
Date   Source Headline
22nd Dec 20177:00 amRNSBlock Listing Six Monthly Return
4th Dec 20177:00 amRNSProposed acquisition of Vamousse
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
1st Dec 20177:00 amRNSAcquisition of AmetopT
17th Oct 20179:14 amRNSHardman Research: Kelo-cote international sales
13th Sep 20177:00 amRNSInterim Results
6th Sep 20177:00 amRNSAppointment of Joint Corporate Broker
1st Aug 20177:00 amRNSNotification of Interim Results
28th Jul 20174:21 pmRNSUpdate on Diclectin
25th Jul 20175:40 pmRNSChanges to interests of a significant shareholder
25th Jul 20175:34 pmRNSChanges to interests of a significant shareholder
18th Jul 20177:00 amRNSHalf Year Trading Update
3rd Jul 20172:29 pmRNSChanges to interests of a significant shareholder
26th Jun 20175:31 pmRNSChanges to interests of a significant shareholder
22nd Jun 20175:22 pmRNSChanges to interests of a significant shareholder
21st Jun 20172:53 pmRNSApplication for block admission
19th Jun 20173:16 pmRNSChanges to interests of a significant shareholder
19th Jun 20172:37 pmRNSApplication for admission
14th Jun 20174:54 pmRNSApplication for admission
25th May 20173:20 pmRNSChanges to interests of a significant shareholder
25th May 201711:00 amRNSResult of AGM
25th May 20177:15 amRNSHardman Res.: Transformed International Business
25th May 20177:00 amRNSAGM Statement
22nd May 201710:10 amRNSApplication for admission
9th May 20171:50 pmRNSCorrection: Application for admission
8th May 20172:30 pmRNSApplication for admission
5th May 20176:10 pmRNSApplication for admission
5th May 20177:00 amRNSChanges to interests of a significant shareholder
5th May 20177:00 amRNSChanges to interests of a significant shareholder
4th May 20171:30 pmRNSChanges to interests of a significant shareholder
28th Apr 201712:15 pmRNSAnnual Report and AGM Notice
28th Apr 20179:45 amRNSChanges to interests of a significant shareholder
24th Apr 201711:33 amRNSChanges to interests of a significant shareholder
5th Apr 20171:30 pmRNSNotification of Major Interest in Shares
31st Mar 20174:59 pmRNSApplication for admission
29th Mar 20177:00 amRNSFull Year Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
2nd Mar 20177:00 amRNSNotification of Preliminary Results
14th Feb 20175:31 pmRNSPDMR shareholding
14th Feb 20175:30 pmRNSApplication for admission
7th Feb 20179:05 amRNSChanges to interests of a significant shareholder
31st Jan 20177:00 amRNSExercise of Share Options
25th Jan 20177:15 amRNSHardman Research: Potential of Diclectin
23rd Jan 20177:00 amRNSPre-Close Trading Update
16th Dec 20164:00 pmRNSExercise of Share Options
15th Dec 20164:50 pmRNSExercise of Share Options
12th Dec 20169:19 amRNSExercise of Share Options
9th Dec 201611:45 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
8th Dec 20167:00 amRNSCapital Markets Event
30th Nov 20164:00 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.